For Patients With No or Limited Drug Coverage
Amgen is committed to assisting patients with no or limited drug coverage access the medicines they need.
Through Amgen’s charitable patient assistance program, Amgen Safety Net Foundation, Amgen supports qualifying patients in the United States who might go without important medicines because of financial barriers. This program provides medicines to patients experiencing financial difficulty at no cost.
Amgen Safety Net Foundation supports financially needy uninsured patients and certain underinsured patients who do not have coverage for particular Amgen medications. Products supported by Amgen Safety Net Foundation include: Aranesp® (darbepoetin alfa), BLINCYTO® (blinatumomab), Corlanor® (ivabradine), Enbrel® (etanercept), EPOGEN® (epoetin alfa) for dialysis use only, IMLYGIC® (talimogene laherparepvec), Kyprolis® (carfilzomib), Neulasta® (pegfilgrastim), NEUPOGEN® (filgrastim), Nplate® (romiplostim), Prolia® (denosumab), Repatha® (evolocumab), Sensipar® (cinacalcet), Vectibix® (panitumumab), and XGEVA® (denosumab). For more information, visit www.amgensafetynetfoundation.com .
This information is intended for residents of the U.S. only.